pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
decent earn perform posit switch studi data broadli expect
show non-inferior trend superior revenu beat aid
benefit strensiq/kanuma soliri roughli line overal revenu guidanc
increas ep increas note mg launch strong patient drug
march track becom best soliri launch
highlight press release/slid call et
switch studi pnh non-inferior good trend favor chart
submiss
 version start late look also advanc
impact clinic trial enrol expect
full year
steadi double-digit growth y/i pnh ahu
mg launch track best soliri far patient drug march
enrol onesourc
nmo ye
benefit chang distributor arrang
benefit time order tender/def revenu
guidanc chart
meaning bump revenu guidanc
gaap ep impact wilson therapeut transact non-gaap ep bump modestli
track respect beat/miss
commentari around product serial around quarter includ
serial guidanc updat
line volum volum impact bycontinu identifi consist number new patient shift mixof patient serv newli identifi patient younger childrenidentif new patient us germani japan expect strensiq rev/pt lower see thatwork payor align valu higher dose yoy growth continu growth germani japannew patient germani japan fund agreement uk franc israel new fund agreement yoy revenu growth volum growthcontinu growth germani japankanumagrowth impact byreach physician lal-d diseas awar diagnot educ programsexpand lab test target enrich pt pop higher likelihood lal-dsplit sale forc strensiq favor order ex-u market previous defer revexpand lab test yoy revenu growth volum growthtim order tender markets/def revenu benefit impact expir batch without revenue recognit yoy growth without chang revenue yoy adjust epsgrowth impact bysolirisadjust salesadjust sg salesoper unfavor impact million trial enrollmentalxn histor quarter perform time benefit latam still underli challeng access new pt start pnh ahu mil impact competitor mil revenue recognit benefit ex-u market identifi new steadi new pt latam still challengetot unfavor impact enrollment-eu apac impact vs price headwind fx headwind volum growth adjust benefit favor order neg impact trial minim contribut gmgnew patient start ahu pnh minim gmg contribut april
roll commentari around pipelin
soliri benefitsoliri limit mg contribut start later year earli mg launch expect limit growth total sg total oper margin total expect tax compani reportsannu revenu guidanc convert follow year april
enrol prevent nmosd studi enrol prevent nmosd data nmo enrol complet data data mid stay focus risk profil nmo data ye mg applic accept review earli know ad commsoliri mg pdufa oct posit mg chmp opinion japan decis earli approv patient onesourc patient current drug strong launch soliri mg track becom best soliri launch patient drug march enrol pnh switch studi pnh soliri nave studi enrol pnh studi soliri nave data pnh soliri nave data pnh soliri nave data pnh soliri nave data present primari secondari non-inferior endpoint met trend toward superior breakthrough hemolysiscomplet enrol adult adolesc ahu studi enrol pnh switch studi pnh soliri switch studi enrol complet data pnh soliri switch studi data pnh soliri switch studi present primari secondari endpoint met trend superioritysubmiss pnh mid enrol pediatr ahu studi enrol adult enrol earli adolesc ahu studi ahu adult complet enrol earli ahu pede adult adult/adolesc data adult adult/adolesc data result support advanc result support advanc start singl pk bridg studi pt pend devic work stabil test human factor bridg studi initi late bridg studi initi late iv pnh patient japan decis earli sad pk trial technolog enrol pt pivot studi mocd type adepriorit partnership blueprint arbusnew biz dev team form focu qualiti rare/ultra-rar sens urgenc disciplinedisciplin biz dev rare diseasestend offer transact wilson therapeut expect close initi studi pt advanc solid fulli written offoth pipelinesoliri product outlook commentari april
deriv valuat base dcf use discount rate appli commerci
stage biotech compani termin growth rate reflect optimist outlook durabl compani
franchis includ contribut soliri myasthenia gravi nmo given concern scientif merit
indic includ product revenu reflect potenti busi develop
risk price target includ intensifi competit threat formid biopharma compani along potenti
amplifi price pressur failur build compel develop pipelin stumbl develop
trial would expect litani downgrad substanti re-rat
articl articl
time dissemin april et
analyst josh schimmer steven breazzano maneka mirchandaney ami liu shenston huang primarili respons
prepar research report attest follow view opinion render research report reflect
person view subject compani issuer part research analyst compens directli
relat specif recommend view research report
